Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 128

1.

Emerging antiangiogenic therapies for non-small-cell lung cancer.

Blakely C, Jahan T.

Expert Rev Anticancer Ther. 2011 Oct;11(10):1607-18. doi: 10.1586/era.11.146. Review.

PMID:
21999134
2.

Targeting the VEGF pathway: antiangiogenic strategies in the treatment of non-small cell lung cancer.

Aita M, Fasola G, Defferrari C, Brianti A, Bello MG, Follador A, Sinaccio G, Pronzato P, Grossi F.

Crit Rev Oncol Hematol. 2008 Dec;68(3):183-96. doi: 10.1016/j.critrevonc.2008.05.002. Epub 2008 Jul 7. Review.

PMID:
18606548
3.

Update on antiangiogenic treatment of advanced non-small cell lung cancer (NSCLC).

Schmid-Bindert G.

Target Oncol. 2013 Mar;8(1):15-26. doi: 10.1007/s11523-013-0261-1. Epub 2013 Feb 1. Review.

PMID:
23371029
4.

Angiogenesis and antiangiogenic agents in non-small cell lung cancer.

Galligioni E, Ferro A.

Lung Cancer. 2001 Dec;34 Suppl 4:S3-7. Review.

PMID:
11742695
5.

New options for integrating antiangiogenic therapy and platinum-based first-line chemotherapy for advanced non-small-cell lung cancer.

Manegold C.

Clin Lung Cancer. 2008;9 Suppl 3:S100-8. doi: 10.3816/CLC.2008.s.015. Review.

PMID:
19419923
6.

Bevacizumab in non-small cell lung cancer.

Di Costanzo F, Mazzoni F, Micol Mela M, Antonuzzo L, Checcacci D, Saggese M, Di Costanzo F.

Drugs. 2008;68(6):737-46. Review.

PMID:
18416583
7.

Angiogenesis inhibition in the treatment of lung cancer.

Vokes E, Herbst R, Sandler A.

Clin Adv Hematol Oncol. 2006 Nov;4(11 Suppl 23):1-10; quiz 11-2. Review.

PMID:
17143257
8.

Targeting tumor neovasculature in non-small-cell lung cancer.

Pallis AG, Syrigos KN.

Crit Rev Oncol Hematol. 2013 May;86(2):130-42. doi: 10.1016/j.critrevonc.2012.10.003. Epub 2012 Nov 15. Review.

PMID:
23159217
9.

Angiogenesis inhibitors and vascular disrupting agents in non-small cell lung cancer.

Rossi A, Maione P, Ferrara ML, Sacco PC, Schettino C, Bareschino MA, Gridelli C.

Curr Med Chem. 2009;16(30):3919-30. Review.

PMID:
19747132
10.

Antiangiogenic therapy in nonsmall cell lung cancer.

Gutierrez M, Giaccone G.

Curr Opin Oncol. 2008 Mar;20(2):176-82. doi: 10.1097/CCO.0b013e3282f4e55e. Review.

PMID:
18300767
11.

Targeting angiogenesis in squamous non-small cell lung cancer.

Piperdi B, Merla A, Perez-Soler R.

Drugs. 2014 Mar;74(4):403-13. doi: 10.1007/s40265-014-0182-z. Review.

12.

Challenges in the current antiangiogenic treatment paradigm for patients with non-small cell lung cancer.

Wozniak A.

Crit Rev Oncol Hematol. 2012 May;82(2):200-12. doi: 10.1016/j.critrevonc.2011.05.003. Epub 2011 Jun 28. Review.

PMID:
21715183
13.

Vascular endothelial growth factor receptor as target for advanced non-small cell lung cancer therapy.

Rossi A, Maione P, Sacco PC, Ambrosio R, Falanga M, Gridelli C.

Curr Drug Targets. 2010 Jul;11(7):865-8784. Review.

PMID:
20412044
14.

Inhibition of angiogenesis in the treatment of non-small cell lung cancer.

Keedy VL, Sandler AB.

Cancer Sci. 2007 Dec;98(12):1825-30. Epub 2007 Sep 24. Review.

15.

Antivascular agents for non-small-cell lung cancer: current status and future directions.

Amir E, Mandoky L, Blackhall F, Thatcher N, Klepetko W, Ankersmit HJ, Reza Hoda MA, Ostoros G, Dank M, Dome B.

Expert Opin Investig Drugs. 2009 Nov;18(11):1667-86. doi: 10.1517/13543780903336050. Review.

PMID:
19877762
16.

[Anti-angiogenic factors in thoracic oncology: successes, failures and prospects].

Marco S, Tomasini P, Greillier L, Barlesi F.

Rev Mal Respir. 2011 Dec;28(10):1216-29. doi: 10.1016/j.rmr.2011.04.014. Epub 2011 Nov 4. Review. French.

PMID:
22152931
17.

Bevacizumab in non-small-cell lung cancer: a review.

Planchard D.

Expert Rev Anticancer Ther. 2011 Aug;11(8):1163-79. doi: 10.1586/era.11.80. Review.

PMID:
21916570
18.

Antiangiogenic agents as second-line therapy for advanced non-small cell lung cancer.

Reckamp KL.

Cancer Lett. 2012 Aug 28;321(2):101-9. doi: 10.1016/j.canlet.2012.01.041. Epub 2012 Feb 3. Review.

PMID:
22306704
19.

Therapeutic options targeting angiogenesis in nonsmall cell lung cancer.

Crinò L, Metro G.

Eur Respir Rev. 2014 Mar 1;23(131):79-91. doi: 10.1183/09059180.00008913. Review.

20.

The potential of antiangiogenic therapy in non-small cell lung cancer.

Giaccone G.

Clin Cancer Res. 2007 Apr 1;13(7):1961-70. Review.

Supplemental Content

Support Center